Mark J. Gergen

2022 - Poseida Therapeutics

In 2022, Mark J. Gergen earned a total compensation of $4.4M as Chief Executive Officer, President and Chairman at Poseida Therapeutics, a 55% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$342,280
Option Awards$1,752,012
Salary$565,750
Stock Awards$1,696,700
Other$12,710
Total$4,369,452

Gergen received $1.8M in option awards, accounting for 40% of the total pay in 2022.

Gergen also received $342.3K in non-equity incentive plan, $565.8K in salary, $1.7M in stock awards and $12.7K in other compensation.

Rankings

In 2022, Mark J. Gergen's compensation ranked 762nd out of 5,733 executives tracked by ExecPay. In other words, Gergen earned more than 86.7% of executives.

ClassificationRankingPercentile
All
762
out of 5,733
87th
Division
Manufacturing
343
out of 3,122
89th
Major group
Chemicals And Allied Products
111
out of 1,416
92nd
Industry group
Drugs
98
out of 1,317
93rd
Industry
Biological Products, Except Diagnostic Substances
22
out of 291
92nd
Source: SEC filing on April 26, 2023.

Gergen's colleagues

We found three more compensation records of executives who worked with Mark J. Gergen at Poseida Therapeutics in 2022.

2022

Brent Warner

Poseida Therapeutics

President, Gene Therapy

2022

Eric Ostertag

Poseida Therapeutics

Chief Executive Officer

2022

Harry Leonhardt

Poseida Therapeutics

General Counsel

News

You may also like